5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Serina Therapeutics, Inc. (NASDAQ:SER), a small-cap biotech company with a market capitalization of $52.5 million, saw its Chief Scientific Officer Randall Moreadith sell 6,500 shares of common stock on October 20, 2025, for approximately $32,286. The shares were sold at prices ranging from $4.88 to $5.02, near the current trading price of $4.98. According to InvestingPro, the company’s overall financial health score is currently rated as WEAK.
On the same day, Moreadith also exercised options to acquire 6,500 shares of Serina Therapeutics common stock at a price of $0.06 per share, for a total value of $390. These options were exercised under a stock option plan that expires on May 6, 2031. InvestingPro analysis reveals 10+ additional insights about Serina’s financial position and future prospects.
Following the sale, Moreadith directly holds no shares of Serina Therapeutics, Inc. common stock. The company maintains a strong liquidity position, with cash reserves exceeding debt obligations, though InvestingPro data indicates rapid cash utilization.
In other recent news, Serina Therapeutics has secured up to $20 million in financing to support the clinical trials of its Parkinson’s disease treatment candidate. The funding, which involves an unsecured convertible note issued in five tranches, is aimed at achieving clinical and operational milestones. Additionally, the company announced receiving supportive feedback from the FDA for its advanced Parkinson’s treatment, SER-252, potentially expediting the approval process through the 505(b)(2) NDA pathway. In another development, Serina Therapeutics has amended its bylaws to address potential conflicts of interest and expand its forum selection clause, as reported in a Securities and Exchange Commission filing. This amendment establishes safe harbor procedures for transactions involving directors, officers, and controlling stockholders. Furthermore, the company is advancing SER-270, a weekly injectable treatment for tardive dyskinesia, utilizing its proprietary POZ polymer technology for improved medication adherence. These developments reflect Serina Therapeutics’ ongoing efforts to advance its pipeline and address key regulatory and operational aspects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.